Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital lowered their price objective on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd.

Evogene Stock Performance

NASDAQ:EVGN opened at $1.62 on Tuesday. The firm has a market cap of $8.69 million, a price-to-earnings ratio of -0.37 and a beta of 1.43. Evogene has a 52 week low of $1.44 and a 52 week high of $10.40. The firm’s 50-day simple moving average is $2.34 and its 200 day simple moving average is $4.37.

Institutional Trading of Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.